Shares of Biocon jumped 5 per cent to Rs 353 on the BSE on Thursday after the company’s biologics manufacturing facilities in Bengaluru received the Establishment Inspection Report (EIR) from the US health regulator.
The stock was trading close to its all-time high level of Rs 359, touched in September 2018.
“Biocon Biologics India, a subsidiary of Biocon, has received the EIR from the US Food and Drug Administration (USFDA) for the Pre-Approval Inspection (PAI) at two of its biologics manufacturing facilities in Bengaluru,” the company said in an exchange filing.
The inspection was conducted between September
The stock was trading close to its all-time high level of Rs 359, touched in September 2018.
“Biocon Biologics India, a subsidiary of Biocon, has received the EIR from the US Food and Drug Administration (USFDA) for the Pre-Approval Inspection (PAI) at two of its biologics manufacturing facilities in Bengaluru,” the company said in an exchange filing.
The inspection was conducted between September